Artiva biotherapeutics reports first quarter 2025 financial results, recent business highlights

Ind clearance and initiation of global basket trial exploring allonk® + rituximab in refractory rheumatoid arthritis, sjÖgren's disease, idiopathic inflammatory myopathies and systemic sclerosis

ARTV Ratings Summary

ARTV Quant Ranking